Letters to the Editor

Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia

Department of Internal Medicine V, Heidelberg University Hospital
Institute of Medical Biometry, University of Heidelberg
NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center
NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center
Institute of Medical Biometry, University of Heidelberg
Institute of Medical Biometry, University of Heidelberg
Department of Medicine IV, Aachen University Hospital, Aachen
Department of Hematology, Oncology and Palliative Medicine, Community Hospital Bielefeld
NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Germany; Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University; Department of Medicine I – Hematology and Cell Therapy, University Hospital Leipzig
Department of Medicine V, Erlangen University Hospital
Department of Medicine A, Münster University Hospital
Department of Hematology and Oncology, St. Josef Brothers’ Hospital Paderborn
Department of Hematology, Oncology and Palliative Medicine, Robert-Bosch Hospital Stuttgart
Department of Internal Medicine, Hematology, Oncology and Palliative Medicine, Prot. Monastery Hospital St. Jakob Koblenz
Department of Hematology, Oncology and Palliative Medicine, Winnenden Hospital, Winnenden
Department of Internal Medicine III - Hematology and Oncology, Red Cross Hospital Munich, Munich
Department of Medicine I – Hematology and Cell Therapy, University Hospital Leipzig
Institute of Medical Biometry, University of Heidelberg
Department of Internal Medicine V, Heidelberg University Hospital
Department of Internal Medicine V, Heidelberg University Hospital, Germany; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center
Haematologica Early view Feb 22, 2024 https://doi.org/10.3324/haematol.2023.284346